ストックスクリーナーアプリを入手
1.63
4.49%
0.07
アフターアワーズ：
1.65
0.02
+1.23%
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderWeekly Trend Recap & Growth Focused Stock Reports - mfd.ru
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Will Cardiff Oncology Inc. stock outperform tech sector in 2025Weekly Stock Report & Free Community Supported Trade Ideas - mfd.ru
Will Cardiff Oncology Inc. outperform its industry peersQuarterly Portfolio Report & Precise Buy Zone Identification - mfd.ru
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
CRDF: New CEO Presents Phase II Readout - Yahoo Finance
Will Cardiff Oncology Inc. (XE7C) stock justify high valuationM&A Rumor & Growth Focused Entry Reports - mfd.ru
Leadership Turmoil Clouds Clinical Progress at Cardiff Oncology - AD HOC NEWS
Ideas Watch: Is Cardiff Oncology Inc likely to announce a buybackWeekly Gains Summary & Safe Entry Trade Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) Is Down 43.9% After Advancing Onvansertib And Reshuffling Leadership Team - Yahoo Finance
Cardiff Oncology Faces Turbulence Amid Leadership Changes - StocksToTrade
CRDF: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus
H.C. Wainwright reiterates Buy rating on Cardiff Oncology stock at $10 - Investing.com Canada
Cardiff Oncology (CRDF) Stock Drop Presents New Investment Oppor - GuruFocus
Why Did Cardiff Oncology Stock Plunge On Tuesday?Cardiff Oncology (NASDAQ:CRDF) - Benzinga
Investors Buy High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - Defense World
Cardiff Oncology appoints interim CEO amid leadership transition By Investing.com - Investing.com India
Cardiff To Pursue Narrower CRC Market For Onvansertib As Top Execs Step Down - Citeline News & Insights
Cardiff Oncology Overhauls Leadership to Advance Onvansertib - TipRanks
Favorite son in PLK1? Cardiff dips as phase II CRC bid advances - BioWorld MedTech
CEO transition at Cardiff Oncology (NASDAQ: CRDF) paired with positive Phase 2 trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cardiff Oncology (CRDF) Shares Plunge After Executive Departures and Trial Update - GuruFocus
Cardiff Oncology Shares Plunge 35% Following CEO and CFO Resignations - Intellectia AI
Cardiff Oncology Sees Unusually Large Options Volume (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Taps Interim CEO, Picks 30mg Onvansertib Regimen for 2026 Registrational mCRC Study - MarketBeat
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - The Globe and Mail
Cardiff Oncology down after leadership shakeup (CRDF:NASDAQ) - Seeking Alpha
Cardiff Oncology stock tumbles after Phase 2 trial data update By Investing.com - Investing.com Canada
Cardiff Oncology plunges after top executives step down - TradingView
Cardiff Oncology (CRDF) Reports Promising Phase 2 Trial Results - GuruFocus
Cardiff Oncology reports positive phase 2 data for cancer drug - Investing.com
Cardiff Oncology reports positive phase 2 data for cancer drug By Investing.com - Investing.com Nigeria
Cardiff Oncology (CRDF) Announces Leadership Changes - GuruFocus
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - The Manila Times
Cardiff Oncology Announces Positive Phase 2 Trial Results for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer - Quiver Quantitative
Cardiff Oncology Announces Positive Update from its - GlobeNewswire
Guidance Update: Can SPAR Group Inc generate free cash flowJuly 2025 Pullbacks & Real-Time Market Sentiment Reports - baoquankhu1.vn
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - ADVFN
CRDFTrovagene Presents Outlook for Second Half of 2018 - ADVFN
CRDF Stock Price, Forecast & Analysis | CARDIFF ONCOLOGY INC (NASDAQ:CRDF) - Chartmill
3 Promising Penny Stocks With Market Caps Below $600M - simplywall.st
How Cardiff Oncology Inc. stock benefits from tech adoptionMorning Star Patterns & Free Long-Term Investment Planning - bollywoodhelpline.com
Gains Recap: Should you buy the dip on Cardiff Oncology Inc2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Will Cardiff Oncology Inc. benefit from sector rotationJuly 2025 Snapshot & Safe Entry Trade Reports - bollywoodhelpline.com
What hedge fund moves indicate for Cardiff Oncology Inc. (XE7C) stock2025 Sector Review & Weekly Setup with ROI Potential - Bollywood Helpline
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Bộ Nội Vụ
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - Улправда
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
Q4 Earnings Estimate for CRDF Issued By Noble Financial - MarketBeat
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
0.15%
1.22%
大文字化:
|
ボリューム (24 時間):